

Considerations for Individualizing CDK 4/6 Inhibitor Therapy in Breast Cancer: Examining the Data and Agent-Specific Attributes

Recorded Podcast References

1. Ciruelos R, Willagrasa P, Pare L, et al. SOLTI-1303 PATRICIA phase II (stage I) — palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas.
2. Tolaney SM, Wardley AM, Zambelli S, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchER): a randomised, open-label, phase 2 trial. *Lancet Oncol*. 2020;21(6):763–75.
3. Finn S, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. *N Engl J Med*. 2016;375(2):1925–36.
4. Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat*. 2019;174(3):719–29.
5. Cristofanili M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicenter, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17(4):425–39.
6. Turner NC, Ro J, André F, et al; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. *N Engl J Med*. 2015;373(3):209–19.
7. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. *N Engl J Med*. 2018;379(20):1926–36.
8. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*. 2018;36(24):2465–72.
9. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. *N Engl J Med*. 2020;382(6):514–24.
10. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol*. 2018;19(7):904–15.
11. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med*. 2019;381(4):307–16.
12. Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2– advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol*. 2017;35(25):2875–84.
13. Sledge GW, Frenzel M. Analysis of overall survival benefit of abemaciclib plus fulvestrant in hormone receptor-positive, ERBB2-negative breast cancer-reply. *JAMA Oncol*. 2020. Online ahead of print.
14. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol*. 2017;35(32):3638–46.
15. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. *Oncologist*. 2017;22(9):1039–48.

16. dos Anjos CH, Razavi P, Herbert J, et al. A large retrospective analysis of CDK 4/6 inhibitor retreatment in ER+ metastatic breast cancer (MBC). *J Clin Oncol*. 2019;37(no. 15_suppl):1053.
17. Palbociclib (Ibrance) [prescribing information]. New York, NY: Pfizer Inc; 2019.
18. Abemaciclib (Verzenio) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2019.
19. Ribociclib (Kisqali) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
20. Tolaney SM, Lin NU, Thornton D, et al. Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer. *J Clin Oncol*. 2017;35(15_suppl):1019.
21. Bachelot T, Kabos P, Yardey D, et al. Abstract P1-17-03: abemaciclib for the treatment of brain metastases secondary to hormone receptor positive breast cancer. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; *Cancer Res*. 2018;78(4 suppl):P1-17-03.
22. Llombart-Cussac A, Perez-Garcia JM, Bellet M, et al: PARSIFAL: A randomized multicenter open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor/HER2– metastatic breast cancer. *J Clin Oncol*. 2020;38(suppl):abstr 1007.